Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study
Eric Bruckert, Sonia Caprio, Albert Wiegman, Min-Ji Charng, Cézar A Zárate-Morales, Marie T Baccara-Dinet, Garen Manvelian, Anne Ourliac, Michel Scemama, Stephen R Daniels, Eric Bruckert, Sonia Caprio, Albert Wiegman, Min-Ji Charng, Cézar A Zárate-Morales, Marie T Baccara-Dinet, Garen Manvelian, Anne Ourliac, Michel Scemama, Stephen R Daniels
Abstract
Background: Despite progress in treating homozygous familial hypercholesterolemia, most patients do not achieve low-density lipoprotein cholesterol (LDL-C) targets. This study examined efficacy and safety of the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, alirocumab, in pediatric patients (aged 8-17 years) with inadequately controlled homozygous familial hypercholesterolemia.
Methods: In this open-label, single-arm, multinational, Phase 3 study, patients (n=18) received alirocumab 75 mg or 150 mg (bodyweight <50 kg/≥50 kg) every 2 weeks as an adjunct to background treatment. The primary endpoint was percent change in LDL-C from baseline to Week 12. Secondary endpoints included changes in LDL-C and other lipid parameters up to 48 weeks, safety/tolerability, and alirocumab pharmacokinetics.
Results: The mean age of patients was 12.4 years; 16/18 (89%) had mutations in the low-density lipoprotein receptor gene (LDLR) and 2/18 (11%) had mutations in the LDLR adapter protein 1 gene (LDLRAP1). At baseline, mean LDL-C (standard deviation) was 373.0 (193.5) mg/dL, which decreased by 4.1% at Week 12 (primary endpoint) and 11.4%, 13.2%, and 0.4% at Weeks 4, 24, and 48, respectively. At Week 12, 9/18 (50%) patients achieved LDL-C reductions ≥15%. Mean absolute LDL-C decreases ranged from 25 to 52 mg/dL over follow-up. A post hoc analysis demonstrated heterogeneity of responses according to genotype. There were no unexpected safety/tolerability findings. Free PCSK9 was reduced to near zero for all patients at Weeks 12 and 24.
Conclusions: The study supports the efficacy and safety of alirocumab as a potential adjunct to treatment for some pediatric patients with homozygous familial hypercholesterolemia.
Registration: URL: https://www.
Clinicaltrials: gov; NCT03510715.
Figures
References
- Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS, Steinhagen-Thiessen E, et al. ; European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia. Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the european atherosclerosis society. Eur Heart J. 2014;35:2146–2157. doi: 10.1093/eurheartj/ehu274
- Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al. ; ESC Scientific Document Group. 2019 esc/eas guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188. doi: 10.1093/eurheartj/ehz455
- Hovingh GK, Goldberg AC, Moriarty PM. Managing the challenging homozygous familial hypercholesterolemia patient: Academic insights and practical approaches for a severe dyslipidemia, a national lipid association masters summit. J Clin Lipidol. 2017;11:602–616. doi: 10.1016/j.jacl.2017.03.008
- Ajufo E, Cuchel M, Cuchel M. Recent developments in gene therapy for homozygous familial hypercholesterolemia. Curr Atheroscler Rep. 2016;18:22 10.1007/s11883-016-0579-0
- Thedrez A, Blom DJ, Ramin-Mangata S, Blanchard V, Croyal M, Chemello K, Nativel B, Pichelin M, Cariou B, Bourane S, et al. . Homozygous familial hypercholesterolemia patients with identical mutations variably express the ldlr (low-density lipoprotein receptor): Implications for the efficacy of evolocumab. Arterioscler Thromb Vasc Biol. 2018;38:592–598. doi: 10.1161/ATVBAHA.117.310217
- Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, Ose L, Averna M, Boileau C, Borén J, et al. ; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia in children and adolescents: Gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36:2425–2437. doi: 10.1093/eurheartj/ehv157
- European Medicines Agency. Evkeeza (evinacumab) summary of product characteristics. 2021. Accessed July 2022.
- European Medicines Agency. Repatha (evolocumab) summary of product characteristics. 2018. Accessed July 2022.
- US Food and Drug Administration. Evkeeza (evinacumab-dgnb) prescribing information. 2021. Accessed July 2022.
- US Food and Drug Administration. Repatha (evolocumab) prescribing information. 2021. Accessed July 2022.
- Landmesser U, Chapman MJ, Farnier M, Gencer B, Gielen S, Hovingh GK, Lüscher TF, Sinning D, Tokgözoglu L, Wiklund O, et al. ; European Society of Cardiology (ESC). European society of cardiology/european atherosclerosis society task force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: Practical guidance for use in patients at very high cardiovascular risk. Eur Heart J. 2017;38:2245–2255. doi: 10.1093/eurheartj/ehw480
- Orringer CE, Jacobson TA, Saseen JJ, Brown AS, Gotto AM, Ross JL, Underberg JA. Update on the use of pcsk9 inhibitors in adults: Recommendations from an expert panel of the national lipid association. J Clin Lipidol. 2017;11:880–890. doi: 10.1016/j.jacl.2017.05.001
- Tomlinson B, Patil NG, Fok M, Lam CWK. Role of pcsk9 inhibitors in patients with familial hypercholesterolemia. Endocrinol Metab (Seoul). 2021;36:279–295. doi: 10.3803/EnM.2021.964
- US Food and Drug Administration. Praluent (alirocumab) prescribing information. 2017. Accessed July 2022.
- Blom DJ, Harada-Shiba M, Rubba P, Gaudet D, Kastelein JJP, Charng MJ, Pordy R, Donahue S, Ali S, Dong Y, et al. . Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: The odyssey hofh trial. J Am Coll Cardiol. 2020;76:131–142. doi: 10.1016/j.jacc.2020.05.027
- European Medicines Agency. Praluent (alirocumab) summary of product characteristics. 2021. Accessed July 2022.
- Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, et al. ; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of ldl cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (London, England). 2010;376:1670–1681. doi: 10.1016/S0140-6736(10)61350-5
- Raal F, Panz V, Immelman A, Pilcher G. Elevated pcsk9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc. 2013;2:e000028. doi: 10.1161/JAHA.112.000028
- Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA; TESLA Investigators. Inhibition of pcsk9 with evolocumab in homozygous familial hypercholesterolaemia (tesla part b): A randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2015;385:341–350. doi: 10.1016/S0140-6736(14)61374-X
- Raal F, Bruckert E, Blom D, Kurtz C, Coll B, Tang L, Somaratne R, Stein EA. Evolocumab treatment in paediatric patients with homozygous familial hypercholesterolaemia: The trial assessing long-term use of pcsk9 inhibition in subjects with genetic LDL disorders (taussig). Euro Soc Cardiol (ESC) Cong. 2017;38(suppl_1):ehx504.3105. 10.1093/eurheartj/ehx504.3105
- Santos RD, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, López JAG, Bray S, Kurtz CE, Hamer AW, et al. . Long-term evolocumab in patients with familial hypercholesterolemia. J Am Coll Cardiol. 2020;75:565–574. doi: 10.1016/j.jacc.2019.12.020
- Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP; Ezetimibe Study Group. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1092–1097. doi: 10.1016/s0002-9149(02)02798-4
- Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP; Ezetimibe Study Group. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24:729–741. doi: 10.1016/s0195-668x(02)00807-2
- Kuehn BM. Evinacumab approval adds a new option for homozygous familial hypercholesterolemia with a hefty price tag. Circulation. 2021;143:2494–2496. doi: 10.1161/CIRCULATIONAHA.121.055463
Source: PubMed